Fierce Biotech May 31, 2024
Helen Floersh

Trial software provider ConcertAI is partnering with Nvidia to develop new clinical simulations that inform future AI products for clinical trials, the company announced May 31 at the American Society of Cancer Oncology’s annual meeting.

“Nvidia Enterprise AI solutions are evolving faster than peers to provide the capability to rapidly build, deploy and manage custom generative AI and predictive AI models in both an efficient and scalable form,” Jeff Elton, Ph.D., CEO of ConcertAI, told Fierce Biotech in an email. “Our past body of work and new solutions now will leverage the Nvidia Enterprise AI capabilities to accelerate model development and deployment for the benefit of our customers and patients who depend on the precision and efficiencies offered by...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Conferences / Podcast, Partnerships, Technology, Trends
Related Articles:
10 signs AI is ‘eating the world (of venture capital)’
2024: record year for AI trials
2025: Provider organizations will embrace new AI and analytics techniques
AI and Automation in Healthcare – 2025 Health IT Predictions
Why The Public And Private Sectors Must Jointly Define Responsible AI

Share This Article